During the last session, Applied Therapeutics Inc. (NASDAQ:APLT)’s traded shares were 0.2 million. At the end of the trading day, the stock’s price was $1.31, reflecting an intraday gain of 8.26% or $0.1. The 52-week high for the APLT share is $19.14, that puts it down -1361.07 from that peak though still a striking 44.27% gain since the share price plummeted to a 52-week low of $0.73. The company’s market capitalization is $32.50M, and the average intraday trading volume over the past 10 days was 0.19 million shares, and the average trade volume was 411.59K shares over the past three months.
Applied Therapeutics Inc. (APLT) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.80. APLT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.78.
Applied Therapeutics Inc. (NASDAQ:APLT) trade information
Applied Therapeutics Inc. (APLT) registered a 8.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.26% in intraday trading to $1.31 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 21.30%, and it has moved by 38.21% in 30 days. Based on these gigs, the overall price performance for the year is -92.96%. The short interest in Applied Therapeutics Inc. (NASDAQ:APLT) is 0.42 million shares and it means that shorts have 0.47 day(s) to cover.
The consensus price target of analysts on Wall Street is $13.38, which implies an increase of 90.21% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.50 and $29.00 respectively. As a result, APLT is trading at a discount of -2113.74% off the target high and -90.84% off the low.
Applied Therapeutics Inc. (APLT) estimates and forecasts
Statistics show that Applied Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Applied Therapeutics Inc. (APLT) shares have gone down -52.36% during the last six months, with a year-to-date growth rate more than the industry average at 24.03% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 21.20% this quarter and then jump 41.30% in the quarter after that.
While earnings are projected to return 3.60% in 2022.
Applied Therapeutics Inc. is due to release its next quarterly earnings between March 16 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Applied Therapeutics Inc. (NASDAQ:APLT)’s Major holders
Applied Therapeutics Inc. insiders own 20.11% of total outstanding shares while institutional holders control 77.40%, with the float percentage being 96.88%. Point72 Asset Management, L.P. is the largest shareholder of the company, while 121 institutions own stock in it. As of Mar 30, 2022, the company held over 2.55 million shares (or 9.72% of all shares), a total value of $5.38 million in shares.
The next largest institutional holding, with 1.6 million shares, is of Franklin Resources, Inc.’s that is approximately 6.08% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $3.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of Applied Therapeutics Inc. (APLT) shares are Franklin Strategic Series-Franklin Biotechnology Discove and Fidelity Select Portfolios – Biotechnology. Data provided on Apr 29, 2022 indicates that Franklin Strategic Series-Franklin Biotechnology Discove owns about 0.73 million shares. This amounts to just over 2.79 percent of the company’s overall shares, with a $1.44 million market value. The same data shows that the other fund manager holds slightly less at 0.6 million, or about 2.27% of the stock, which is worth about $0.86 million.